Diagnostic Accuracy of Contrast-Enhanced Ultrasound Liver Imaging Reporting and Data System (CEUS LI-RADS) for Differentiating Between Hepatocellular Carcinoma and Other Hepatic Malignancies in High-Risk Patients: A Meta-Analysis
- PMID: 33307595
- DOI: 10.1055/a-1309-1568
Diagnostic Accuracy of Contrast-Enhanced Ultrasound Liver Imaging Reporting and Data System (CEUS LI-RADS) for Differentiating Between Hepatocellular Carcinoma and Other Hepatic Malignancies in High-Risk Patients: A Meta-Analysis
Abstract
Objectives: The American College of Radiology (ACR) contrast-enhanced ultrasound liver imaging reporting and data system (CEUS LI-RADS), which includes diagnostic criteria for hepatocellular carcinoma (HCC) and other hepatic malignancies (OM), is increasingly used in clinical practice. This study performed a meta-analysis to assess the diagnostic accuracy of CEUS LI-RADS for differentiating between HCC and OM in high-risk patients.
Methods: PubMed, Embase (Ovid), and Cochrane (CENTRAL) were searched for relevant studies. All studies that reported the percentage of HCC and OM in the LI-RADS categories were included. Random-effects models were used to calculate the pooled sensitivity and specificity, diagnostic odds ratio (DOR), and summary receiver operating characteristic (SROC) curve.
Results: Eight studies involving 4215 focal liver lesions were included in the final analysis. The pooled sensitivity and specificity of the LR-5 criteria for HCC were 0.71 (95 % CI, 0.69-0.72) and 0.88 (0.85-0.91), respectively, the DOR was 18.36 (7.41-45.52), and the area under the SROC curve (AUC) was 0.8128. The pooled sensitivity and specificity of the LR-M criteria for OMs were 0.85 (0.81-0.88) and 0.86 (0.85-0.87), the DOR was 27.82 (11.83-65.40), respectively, and the SROC AUC was 0.9098.
Conclusion: The CEUS LI-RADS can effectively distinguish HCC from other hepatic malignancy in high-risk patients based on LR-5 criteria and LR-M criteria. However, further studies are needed for validation due to the limited number of included studies and the potential heterogeneity among the included studies.
ZIEL: Das kontrastverstärkte Ultraschall-Berichts- und Datensystem für die Leberbildgebung (CEUS-LI-RADS) des American College of Radiology (ACR), das diagnostische Kriterien für das hepatozelluläre Karzinom (HCC) und maligne Lebererkrankungen (OM) beinhaltet, wird in der klinischen Praxis zunehmend eingesetzt. Diese Studie führte eine Metaanalyse durch, um die diagnostische Genauigkeit von CEUS-LI-RADS zur Differenzierung zwischen HCC und OM bei Hochrisikopatienten zu beurteilen.
Methoden: PubMed, Embase (Ovid) und Cochrane (CENTRAL) wurden nach relevanten Studien durchsucht. Einbezogen wurden alle Studien, in denen der Prozentsatz von HCC und OM in den LI-RADS-Kategorien angegeben wurde. Random-effect-Modelle wurden verwendet, um die gepoolte Sensitivität und Spezifität, die diagnostische Odds Ratio (DOR) und die summierte Receiver-Operating-Characteristic (SROC)-Kurve zu berechnen.
Ergebnisse: Acht Studien mit 4215 fokalen Leberläsionen wurden in die abschließende Analyse einbezogen. Die gepoolte Sensitivität der LR-5-Kriterien für das HCC betrug 0,71 (95 %-KI 0,69–0,72) und die gepoolte Spezifität 0,88 (0,85–0,91), die DOR 18,36 (7,41–45,52) und die AUC (Area Under the Curve) der SROC 0,8128. Die gepoolte Sensitivität der LR-M-Kriterien für OMs betrug 0,85 (0,81–0,88) und die gepoolte Spezifität 0,86 (0,85–0,87), die DOR 27,82 (11,83–65,40) und die SROC-AUC 0,9098.
Schlussfolgerung: CEUS-LI-RADS kann ein HCC anhand von LR-5-Kriterien und LR-M-Kriterien wirksam von anderen malignen Lebererkrankungen bei Hochrisikopatienten unterscheiden. Aufgrund der begrenzten Anzahl der eingeschlossenen Studien und deren potenzieller Heterogenität sind jedoch weitere Studien zur Validierung erforderlich.
Thieme. All rights reserved.
Conflict of interest statement
The authors declare that they have no conflict of interest.
Similar articles
-
MR versus CEUS LI-RADS for Distinguishing Hepatocellular Carcinoma from other Hepatic Malignancies in High-Risk Patients.Ultrasound Med Biol. 2021 May;47(5):1244-1252. doi: 10.1016/j.ultrasmedbio.2021.01.020. Epub 2021 Feb 18. Ultrasound Med Biol. 2021. PMID: 33610338
-
Risk stratification for hepatocellular carcinoma of contrast-enhanced ultrasound Liver Imaging Reporting and Data System (LI-RADS) and the diagnostic performance of LR-5 and LR-M: a systematic review and meta-analysis.Clin Radiol. 2022 Apr;77(4):e280-e286. doi: 10.1016/j.crad.2022.01.041. Epub 2022 Feb 12. Clin Radiol. 2022. PMID: 35164930
-
Diagnostic Accuracy of CEUS LI-RADS for the Characterization of Liver Nodules 20 mm or Smaller in Patients at Risk for Hepatocellular Carcinoma.Radiology. 2020 Feb;294(2):329-339. doi: 10.1148/radiol.2019191086. Epub 2019 Dec 3. Radiology. 2020. PMID: 31793849
-
Diagnostic accuracy of contrast-enhanced ultrasound for the differential diagnosis of hepatocellular carcinoma: ESCULAP versus CEUS-LI-RADS.Eur J Gastroenterol Hepatol. 2017 Sep;29(9):1036-1044. doi: 10.1097/MEG.0000000000000916. Eur J Gastroenterol Hepatol. 2017. PMID: 28562394
-
Accuracy of contrast-enhanced ultrasound liver imaging reporting and data system: a systematic review and meta-analysis.Hepatol Int. 2020 Dec;14(6):1104-1113. doi: 10.1007/s12072-020-10102-5. Epub 2020 Nov 10. Hepatol Int. 2020. PMID: 33170416
Cited by
-
The Relationship between Ultrasonographic Features of Hepatocellular Carcinoma and the Severity of Hepatocellular Carcinoma and the Expression of PTEN and Tg737.J Healthc Eng. 2022 Mar 24;2022:2608633. doi: 10.1155/2022/2608633. eCollection 2022. J Healthc Eng. 2022. Retraction in: J Healthc Eng. 2023 Oct 4;2023:9848563. doi: 10.1155/2023/9848563. PMID: 35368955 Free PMC article. Retracted.
-
Epidemiology of Hepatocellular Carcinoma in Taiwan.Clin Pract. 2024 Mar 28;14(2):570-578. doi: 10.3390/clinpract14020044. Clin Pract. 2024. PMID: 38666802 Free PMC article.
-
Imaging diagnosis of hepatocellular carcinoma: Future directions with special emphasis on hepatobiliary magnetic resonance imaging and contrast-enhanced ultrasound.Clin Mol Hepatol. 2022 Jul;28(3):362-379. doi: 10.3350/cmh.2021.0361. Epub 2021 Dec 27. Clin Mol Hepatol. 2022. PMID: 34955003 Free PMC article. Review.
-
Risk Stratification and Distribution of Hepatocellular Carcinomas in CEUS and CT/MRI LI-RADS: A Meta-Analysis.Front Oncol. 2022 Mar 29;12:873913. doi: 10.3389/fonc.2022.873913. eCollection 2022. Front Oncol. 2022. PMID: 35425706 Free PMC article.
-
A proposed lung ultrasound and phenotypic algorithm for the care of COVID-19 patients with acute respiratory failure.Can J Anaesth. 2020 Oct;67(10):1393-1404. doi: 10.1007/s12630-020-01704-6. Epub 2020 May 21. Can J Anaesth. 2020. PMID: 32440906 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical